Common and Serious Orlistat Side Effects

Orlistat’s most frequent side effects are gastrointestinal, including oily stools, fecal urgency, and oily spotting, and they affect more than a quarter of people who take the drug. These problems are a direct and predictable consequence of how orlistat works: it blocks fat digestion, so undigested fat has to go somewhere. But while the gut-related effects get the most attention, orlistat also carries rarer and more serious risks involving the kidneys, liver, and gallbladder, along with interactions with several common medications that can catch people off guard.

Why Orlistat Causes the Side Effects It Does

Orlistat works by blocking the enzymes in your stomach and small intestine that break down dietary fat. In healthy volunteers, orlistat inhibited gastric lipase by roughly 47 to 91 percent and pancreatic lipase by about 51 to 83 percent, depending on the type of meal eaten.¹ The fat that isn’t broken down can’t be absorbed through the intestinal wall, so it passes straight through your digestive tract and comes out in your stool. In studies with solid meals, anywhere from about 40 to 57 percent of the ingested fat ended up excreted rather than absorbed.¹ That large volume of undigested fat moving through the bowel is what drives nearly all the common complaints.

This also means the side effects are dose-dependent in a practical sense. The more fat in a meal, the more undigested fat in the gut, and the worse the symptoms. Someone who eats a low-fat meal before taking orlistat will have a far milder experience than someone who eats a greasy one. The drug doesn’t enter the bloodstream in any meaningful amount; it acts almost entirely inside the gut. That local action is why the side-effect profile is so heavily weighted toward gastrointestinal problems rather than the systemic effects you see with many other medications.

The Common Gastrointestinal Effects

A 2024 review in JAMA noted that gastrointestinal side effects, such as oily fecal spotting and urgency, occur in more than 25 percent of patients taking orlistat.² In practice, the list of common complaints includes oily or fatty stools, increased frequency of bowel movements, fecal urgency (the sudden, hard-to-delay need to use the bathroom), flatulence with oily discharge, and oily spotting on underwear. These effects tend to be worst in the first few weeks of treatment and generally ease over time as people learn to moderate their fat intake.

The oily spotting in particular has been studied in detail. Research on obese patients taking orlistat found that the drug increased both stool volume and the fat and water content of stool. People who were susceptible to spotting tended to have lower rectal compliance, heightened rectal sensitivity, and weaker resting sphincter pressure compared to those who weren’t spotters.³ In other words, individual anatomy plays a role. Two people eating the same meal and taking the same dose can have quite different experiences. Some people barely notice the drug, while others find it socially disruptive.

These gastrointestinal effects are also the primary reason people stop taking orlistat. A meta-analysis found that people on orlistat were about 59 percent more likely to discontinue treatment due to adverse events compared to those on placebo, and gastrointestinal problems accounted for roughly 40 percent of all withdrawals.⁴ The absolute difference was modest, about 3 percent more people dropping out than on placebo, but the pattern is clear: the gut effects, not anything more medically serious, are what drive most people away from the drug.

Fat-Soluble Vitamin Depletion

Because orlistat blocks fat absorption, it also reduces the absorption of vitamins that dissolve in fat: vitamins A, D, E, and K. This is not a theoretical concern. A study in obese adolescents found that absorption of vitamin E was significantly reduced during orlistat treatment, and vitamin D levels dropped significantly after just one month, even though participants were taking a daily multivitamin.⁵ Vitamin K levels showed a trend downward as well, which matters for blood clotting. Vitamin A absorption and serum levels were less affected in that study, but the concern persists across all four fat-soluble vitamins with longer use.

This is why a daily multivitamin is standard advice for anyone on orlistat.⁶ The recommended practice is to take the multivitamin at least two hours before or after your orlistat dose, so the drug doesn’t immediately block absorption of the supplement’s fat-soluble contents. Even with supplementation, some people may still need additional vitamin D, as seen in a tolerability study of adolescents where three subjects needed extra vitamin D on top of their daily multivitamin.⁷

Kidney Damage From Oxalate Buildup

One of orlistat’s most serious and underappreciated risks involves the kidneys. When fat isn’t absorbed in the gut, it binds to calcium that would normally bind to oxalate, a waste product from food. Without calcium to grab onto, oxalate is absorbed in higher amounts and ends up in the urine, where it can form calcium oxalate crystals. Those crystals can deposit in the kidney tubules and cause what’s called oxalate nephropathy, which in some cases leads to acute kidney injury or chronic kidney disease.

This isn’t just theoretical biochemistry. Case reports have documented kidney failure in patients taking orlistat. In one early case, a woman with pre-existing chronic kidney disease developed acute kidney injury after her orlistat dose was increased. Her urine was full of calcium oxalate crystals, and a kidney biopsy confirmed oxalate deposits in the tubules.⁸ In another report, two patients developed kidney failure from oxalate deposition while on orlistat, prompting the authors to call oxalate nephropathy an under-recognized cause of chronic kidney disease in orlistat users.⁹

A particularly striking case involved a kidney transplant candidate who had been using orlistat for six months as part of a pre-transplant weight-loss program. Three weeks after receiving a donor kidney, a biopsy showed extensive calcium oxalate deposits, and the transplanted kidney never recovered function.¹⁰ The lesson from these cases is that anyone with pre-existing kidney problems, a history of kidney stones, or plans for a transplant should be especially cautious about orlistat. The risk is rare in the general population, but when it happens, the damage can be irreversible.

Liver and Gallbladder Concerns

Reports of liver injury during orlistat treatment exist, though they are uncommon. A critical review of orlistat’s safety profile noted that a few cases of serious hepatic adverse effects had been reported, including gallstones, cholestatic hepatitis, and subacute liver failure.¹¹ The mechanism linking orlistat to liver damage isn’t well established, and the absolute number of reported cases is small relative to the millions of prescriptions written. Regulatory agencies have added liver injury warnings to the label, but it remains a rare event.

Gallstones are a more nuanced issue because rapid weight loss itself is a well-known risk factor for gallstone formation, making it hard to pin blame entirely on the drug. In a randomized trial of obese adolescents, six participants in the orlistat group developed asymptomatic gallstones during the study, and five of those six had lost large amounts of weight. One participant who lost nearly 16 kilograms developed multiple gallstones and needed surgery to remove the gallbladder.¹² In a separate year-long study of adults, three out of 40 patients developed gallstones, though two of those were in the placebo group and had also lost a lot of weight.¹³

There’s a plausible mechanism for why orlistat might add to the baseline gallstone risk from weight loss. By blocking fat digestion, orlistat reduces the release of cholecystokinin, a hormone that triggers gallbladder contraction after meals. If the gallbladder doesn’t contract and empty as vigorously, bile can stagnate and form stones. That said, an earlier crossover study in healthy subjects found that a single dose of orlistat didn’t significantly reduce gallbladder motility.¹⁴ The picture with long-term use and larger doses may differ. The practical takeaway is that the combination of orlistat and rapid weight loss warrants monitoring, and anyone with a history of gallbladder problems should discuss this risk with their doctor before starting.

Drug Interactions Worth Knowing About

Orlistat can interfere with the absorption of several important medications. Because it alters how fat and fat-soluble substances move through the gut, drugs that depend on fat for absorption or that are sensitive to changes in vitamin levels can be affected in ways that are clinically meaningful.

Cyclosporine: Orlistat markedly decreased blood levels of cyclosporine in an obese heart transplant patient, likely by interfering with intestinal absorption. The authors recommended against using the two drugs together due to the risk of dangerous under-immunosuppression.¹⁵
Warfarin: Because orlistat reduces absorption of vitamin K, it can shift the balance of anticoagulation. Case reports have documented enhanced warfarin effect during orlistat treatment, meaning the blood becomes thinner than expected and bleeding risk rises. People on warfarin who start orlistat may need their dose adjusted and their clotting monitored more frequently.¹⁶
Levothyroxine: Orlistat can impair the absorption of levothyroxine, the synthetic thyroid hormone used by millions of people with hypothyroidism. A systematic review identified orlistat as one of several medications that can bind to levothyroxine in the gut and reduce its bioavailability.¹⁷ Anyone on thyroid medication should separate their doses from orlistat by at least four hours and have their thyroid levels rechecked after starting the drug.

The cyclosporine interaction is especially dangerous because transplant patients depend on consistent immunosuppression to prevent organ rejection. Even modest drops in cyclosporine levels can have severe consequences. This interaction, combined with the oxalate nephropathy risk described earlier, makes orlistat a poor fit for most transplant recipients.

Reducing the Side Effects

The most effective way to minimize orlistat’s gastrointestinal effects is straightforward: eat less fat. Since the drug blocks fat digestion, a meal containing 15 grams of fat will produce far less undigested residue than one with 40 grams. Most guidance suggests keeping fat at about 30 percent or less of total calories per meal, spread relatively evenly across the day rather than concentrated in one large fatty meal.

Beyond dietary adjustment, research has explored adding fiber supplements. A study found that psyllium fiber, taken alongside orlistat, was effective and safe in controlling the gastrointestinal side effects.¹⁸ The idea is that fiber absorbs some of the excess water and oil in the gut, firming up stool and reducing oily discharge. Researchers have also experimented with modified drug formulations: one study developed a combination of orlistat mini-tablets paired with xanthan gum tablets and found that the formulation produced significantly less oily stool in animal testing compared to standard orlistat capsules.¹⁹

For the vitamin deficiency issue, timing matters. Taking a daily multivitamin that includes vitamins A, D, E, and K at bedtime (when your last orlistat dose was at dinner) gives the vitamins a better chance of being absorbed without immediate interference from the drug.

The Side Effects as a Behavioral Tool

Orlistat has an unusual psychological dimension that sets it apart from most medications. A qualitative study exploring patient experiences found that the visible, oily side effects served as a kind of biofeedback mechanism for some users. People who saw oily discharge after a high-fat meal could make a direct, visual connection between the food they ate and its consequences. For patients who were already motivated by a health scare or life crisis, this visceral link helped shift their beliefs about what was causing their weight gain and made lasting dietary changes more likely.²⁰

For others, the same side effects had the opposite result. They found the oily stool and spotting so embarrassing or inconvenient that they simply stopped taking the drug rather than changing their diet. The study captured this split neatly: motivation and context determined whether the side effects became a teacher or a dealbreaker. Some prescribers frame the gastrointestinal effects as a feature rather than a bug when discussing orlistat with patients, arguing that the immediate physical feedback reinforces healthier eating in a way that no amount of nutritional counseling can replicate. Whether that framing is helpful or patronizing probably depends on the person sitting across the desk.

Orlistat in Adolescents

Orlistat is one of the few weight-loss medications approved for use in adolescents (typically ages 12 and older). The side-effect profile in younger patients looks broadly similar to that in adults: mostly gastrointestinal complaints that are mild to moderate in intensity and decrease over time.²¹ A three-month tolerability study found that adolescents reported side effects limited to the same gastrointestinal effects seen in adults, with 85 percent of participants completing treatment.⁷

The vitamin depletion concern is arguably more important in adolescents than in adults, because teenagers are still growing and building bone density. The finding that vitamin D dropped significantly within a month of starting orlistat despite multivitamin supplementation is more alarming in a 14-year-old than in a 45-year-old.⁵ Gallstone risk also appeared in the adolescent randomized trial, where six orlistat-group participants developed stones.¹² Careful monitoring of vitamin levels and periodic abdominal imaging are reasonable precautions in this age group.

Lipase Inhibitors With Fewer Gut Effects

Given that the gastrointestinal side effects are the main reason people abandon orlistat, pharmaceutical researchers have tried to develop lipase inhibitors that achieve similar weight loss with less intestinal disruption. One alternative, cetilistat, was tested in a 12-week randomized trial. While participants still experienced more gastrointestinal events than those on placebo, the rates of specific complaints like oily spotting and flatulence with discharge were notably low, ranging from roughly 2 to 3 percent across the cetilistat-treated groups.²² For comparison, those same complaints affect well over a quarter of orlistat users. Cetilistat is approved in Japan but not widely available elsewhere, so for most people orlistat remains the only lipase-inhibitor option on pharmacy shelves. The existence of cetilistat does suggest, though, that the extreme gut effects of orlistat aren’t an inevitable price of blocking fat absorption; they may partly reflect the drug’s specific formulation and dosing rather than an immovable ceiling of the lipase-inhibitor approach.